Ebola vaccine safety study for healthy people
Part of Infections clinical trials.
This study tests a new Ebola vaccine to see if it is safe and how well it works. Healthy volunteers receive the vaccine and are monitored for side effects and immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 and 65 years old (or 18–50 for the first part).
- You must live in the study community and have a permanent home address.
- You must be generally healthy, with stable medical conditions allowed in the second part.
- You must not have had an Ebola vaccine before or a history of Ebola virus disease.
- You must not be pregnant, breastfeeding, or planning to become pregnant during the study.
- You must agree to use contraception if you are of childbearing age and sexually active.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental vaccine designed to protect against Sudan virus, a rare but serious disease. Researchers will check if the vaccine is safe and helps your immune system fight off the virus.
This study tests if a booster dose of one of two Ebola vaccines (Ervebo® or Zabdeno®) is safe and works well in people who already got an Ebola vaccine more than 4 months ago. It's especially for people living in the Democratic Republic of Congo (DRC) who may have been vaccinated before and might need a stronger, longer-lasting immune response.
This study looks at whether giving an Ebola treatment (Inmazeb) before the Ebola vaccine (Ervebo) changes the vaccine's effect on healthy people. It helps understand the best timing for these treatments.
This study tests a new vaccine, V4020, that may help protect against Venezuelan equine encephalitis (VEE), a rare but serious virus spread by mosquitoes. It is the first step in humans to see if it is safe and how the body responds.
This trial tests a new medicine to prevent Ebola after you have been exposed. If you had close contact with someone who has Ebola in the last 5 days, this study could help you stay healthy.
This trial provides an experimental antibody treatment called REGN-EB3 to people infected with Ebola virus. It aims to treat the infection and potentially improve recovery, and is available through special access in areas with Ebola outbreaks.
Hear when a new Sudan Ebola Virus Vaccines trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.